{
  "docId": "019dd923-622b-71dc-a6d9-fc4318e06f9b",
  "docSlug": "6ded4b1cfe2c",
  "documentTitle": "Bristol-Myers Squibb Company (BMY)",
  "authorId": "03_Starboard_Value",
  "authorName": "Starboard Value",
  "documentKindSlug": "activist-deck",
  "documentKindLabel": "Activist deck",
  "sourceTypeSlug": "activist_investor",
  "sourceTypeLabel": "Activist investor",
  "presentationDate": "2019-03-18 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.3333334,
  "pageNumber": 153,
  "pageCount": 197,
  "prevPage": 152,
  "nextPage": 154,
  "slideType": "peer_benchmark",
  "function": "compare_peers",
  "density": "dense",
  "nDataPoints": 5,
  "notes": "The slide uses a precedent (Amgen) to argue for a specific operational strategy at the target company (Bristol-Myers).",
  "elementsJson": [
    "headline_text",
    "subtitle_text",
    "screenshot",
    "bar_chart_vertical",
    "footnote"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622b-71dc-a6d9-fc4318e06f9b/153",
  "deckHref": "/decks/019dd923-622b-71dc-a6d9-fc4318e06f9b",
  "deckJsonHref": "/decks/019dd923-622b-71dc-a6d9-fc4318e06f9b.json",
  "deckAnchorHref": "/decks/019dd923-622b-71dc-a6d9-fc4318e06f9b#slide-153",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "We believe Bristol-Myers may have an opportunity to embark upon a similar margin improvement plan",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd953-64d3-706e-a454-0ab2d6434dd3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.38,
        "w": 0.44,
        "x": 0.53,
        "y": 0.31
      },
      "kind": "chart",
      "text": "LTM Adj. EBITDA Margins: BMY (36%) vs Direct Peers (48%) vs Amgen (53%)",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3e7373c0-ca05-4307-a829-561fe950fc6e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.38,
        "w": 0.46,
        "x": 0.03,
        "y": 0.31
      },
      "kind": "chart",
      "text": "2014 Amgen Management Presentation: Improving Operating Margin by ~ 15 Points",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "78cf44a0-ff0d-45d3-a535-56eb29106e0c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "metric",
      "text": "LTM Adj. EBITDA Margins: 36%",
      "attrs": null,
      "subkind": "primary",
      "toolName": "Quantification",
      "toolSlug": "quantification",
      "confidence": null,
      "componentId": "019dd953-64d3-706e-a454-0e45a8b58e62",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.92,
        "x": 0.04,
        "y": 0.15
      },
      "kind": "paragraph",
      "text": "Due to Amgen's execution of a margin improvement plan over the past several years, its margins are now significantly higher than Bristol-Myers'.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8130b44e-c45f-4358-9eb4-33fb9d57d518",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.98,
        "x": 0.01,
        "y": 0.94
      },
      "kind": "source-note",
      "text": "Source: Public company filings. (1) Bristol-Myers is adjusted for one-time items... (2) Starboard selected Direct Peers include: ABBV, AMGN, BIIB, MRK, CPSE:NOVO.B, SWX:ROG.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "aba1e967-a6ea-471b-b0b2-7b1b8ab24ea4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.92,
        "x": 0.04,
        "y": 0.89
      },
      "kind": "title",
      "text": "We believe Bristol-Myers may have an opportunity to embark upon a similar margin improvement plan",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "97507855-f4db-4e77-929b-de0fc12ae5a0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.92,
        "x": 0.04,
        "y": 0.03
      },
      "kind": "title",
      "text": "Amgen's Margin Improvement Plan Provides a Blueprint for Bristol-Myers (cont'd)",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "15faa709-4ea3-4440-bcd0-a86124077fff",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Slide recipe: the peer-gap chart",
      "slug": "peer-gap-chart-recipe",
      "agent": "designer",
      "layer": "slide",
      "matchId": "29b1bd04-3072-4475-afa3-52f78093dd8a",
      "evidence": "The slide compares Bristol-Myers' LTM Adj. EBITDA Margins to its direct peers and Amgen, using a bar chart.",
      "confidence": 0.8
    }
  ],
  "frameworks": [
    {
      "name": "comparison_frame",
      "slug": null,
      "matchId": "030bf42b-25d2-486f-86bd-c017024e496e",
      "evidence": "Comparing target company margins against a successful peer precedent to justify a strategic shift.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}